Bernard Davitian
Plus aucun poste en cours
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Otello Stampacchia | M | 55 |
Omega Fund Management LLC
 Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 20 ans |
| Jenny Robertson | F | 50 | 2 ans | |
| John Hood | M | - |
Endeavor BioMedicines, Inc
 Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | - |
| Francesco Draetta | M | 39 |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 8 ans |
| Miguel A. de los Ríos | M | 49 |
Endeavor BioMedicines, Inc
Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | - |
| Brenda Cooperstone | M | 59 | 1 ans | |
| E. Sutherland | M | 54 | 2 ans | |
| Katie Kerfoot | F | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 5 ans |
| Roshawn Blunt | F | 49 |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 1 ans |
| John Maraganore | M | 60 |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 2 ans |
| Mark Russell | M | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 14 ans |
| Jonathan Silverstein | M | - | - | |
| Sanjaya Singh | M | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 1 ans |
| Richard Lim | M | 52 |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 16 ans |
| Mette Agger | F | 59 | 4 ans | |
| Paula Cholmondeley | F | 77 | 3 ans | |
| Reinaldo Diaz | M | 70 | 2 ans | |
| Steven Altschuler | M | 70 | 3 ans | |
| Benoît Habert | M | 59 | 24 ans | |
| James Sullivan | M | - | - | |
| Deirdre Cunnane | F | 59 |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 5 ans |
| Alex Delbridge | M | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 3 ans |
| Edd Fleming | M | - |
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 ans |
| Noelle Hutchins | F | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 4 ans |
| Gilchrist DiPrete | M | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 6 ans |
| Ryan McHenry | M | - | 2 ans | |
| Marcella Ruddy | M | - |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 ans |
| Aimee Black | F | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 1 ans |
| Mona Ashiya | F | - | - | |
| Paul McCormac | M | 54 | 3 ans | |
| Michael Powell | M | 69 |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 3 ans |
| Christopher Gagliardi | M | - |
Sanofi Ventures
 Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | 7 ans |
| Annie Mitsak | M | 40 |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 9 ans |
| Michelle Doig | F | 50 |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 8 ans |
| Alex Rosen | M | - |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 1 ans |
| Jason Hafler | M | 42 |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | 10 ans |
| Eric Adler | M | 44 | 2 ans | |
| Chen-Ming Yu | M | 50 |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | 3 ans |
| Laia Crespo | M | - |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | 6 ans |
| Alexia Pearsall | F | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 4 ans |
| Claudio Nessi | M | 56 |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 8 ans |
| Olivia Mitchell | F | 71 |
The Wharton School of the University of Pennsylvania
| 31 ans |
| Vincent Ossipow | M | 55 |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 10 ans |
| Keith Wonnacott | M | - | 3 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Bernard Gilly | M | 67 |
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | 13 ans |
| Edward Danse | M | - |
Neurotech Pharmaceuticals, Inc. (United States)
 Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI. | 9 ans |
| Phil Bronner | M | 53 |
The Wharton School of the University of Pennsylvania
| 3 ans |
| Alan Walts | M | 64 |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | - |
| Ann DeWitt | M | - |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | 3 ans |
| Arnaud Fayet | M | 83 | - | |
| Justin Warren Slatky | M | - |
The Wharton School of the University of Pennsylvania
| 5 ans |
| Anne-Mari Paster | F | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | 15 ans |
| Matthew Young | M | 54 |
The Wharton School of the University of Pennsylvania
| 5 ans |
| Andrew Pearson | M | 52 |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Maja M. Gross | F | - |
The Wharton School of the University of Pennsylvania
| 6 ans |
| Daniel Mansuri | M | - |
Sanofi Ventures
Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | 3 ans |
| Donald Williams | M | - |
Arthur Andersen LLP
 Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | - |
| Reagan S. Busbee | M | - |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | 6 ans |
| Antoine Papiernik | M | 56 |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets.
The Wharton School of the University of Pennsylvania
| 7 ans |
| Jason Haber Karp | M | 47 |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Pete Labbat | M | 59 |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Josh Birnbaum | M | - |
The Wharton School of the University of Pennsylvania
| 3 ans |
| Fernando Dasso Montero | M | 59 |
The Wharton School of the University of Pennsylvania
| 2 ans |
| John Noble George Wilson | M | 60 |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Donald Timothy Wood | M | - |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Neil M. Barofsky | M | 54 |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Jeanette L. Ourada | F | 58 |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Roman Kudryashov | M | 57 |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Tolga Habip | M | - |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Luv Dinesh Parikh | M | 48 |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Marla Blow | F | 53 |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Keith Alexander | M | - |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Reid Schneider | M | - |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Christopher Thomas | M | 49 |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Lorne Abramson | M | - |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Theodore Coons | M | - |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Oliver Boulind | M | 53 |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Harley Lank | M | - |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Nicolas Roberto Galperin | M | 55 |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Roger Cozzi | M | 54 |
The Wharton School of the University of Pennsylvania
| 4 ans |
| James Scott Corl | M | 57 |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Jeff L. Mobley | M | 55 |
The Wharton School of the University of Pennsylvania
| 2 ans |
| John Wang | M | - |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Marc A. Singer | M | - |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Caroline Curry | F | - |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Eric Filipek | M | - |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Mark Alan Mowrey | M | - |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Peter Lee | M | - |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Marcos Eduardo Galperin | M | 51 |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Stockton Croft | M | - |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Lawrence I. Shagrin | M | - |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Alex Gorsky | M | 63 |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Adam Gregory Tuckman | M | - |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Tyler J. Wolfram | M | 57 |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Michael A. Pollack | M | - |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Eric Edward Alt | M | - |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Samantha Joy Greenberg | F | - |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Craig L. Farlie | M | - |
The Wharton School of the University of Pennsylvania
| 2 ans |
| Judith W. Ottensoser | F | - |
The Wharton School of the University of Pennsylvania
| 4 ans |
| Andrie Setiawan Yapsir | M | 64 |
The Wharton School of the University of Pennsylvania
| 2 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 91 | 91,00% |
| France | 4 | 4,00% |
| Royaume-Uni | 2 | 2,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Bernard Davitian
- Réseau Personnel
